modelJ05AP52
Extends from Pharmacokinetic.Models.PK_2C_enteral.
Information
| name: | DasabuvirOmbitasvirParitaprevirAndRitonavir | |
| ATC code: | J05AP52 | route: | oral |
| compartments: | 2 | |
| dosage: | 25 | mg |
| volume of distribution: | 103 | L |
| clearance: | 15.1 | L/h |
| other parameters in model implementation | ||
Dasabuvir, ombitasvir, paritaprevir, and ritonavir is a fixed-dose combination regimen used as antiviral therapy for chronic hepatitis C virus (HCV) infection. Paritaprevir (an NS3/4A protease inhibitor) is boosted with ritonavir (a CYP3A inhibitor), ombitasvir is an NS5A inhibitor, and dasabuvir is a non-nucleoside NS5B polymerase inhibitor. This fixed combination (also marketed as Viekira Pak) is approved for the treatment of HCV genotype 1 and was widely used but has been largely superseded by newer regimens.
Pharmacokinetics
Pharmacokinetic parameters for healthy adult subjects after oral administration (fed state). Parameters are predominantly derived from population PK and single/multiple dose studies.
References
Mensing, S, et al., & Dutta, S (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. The AAPS journal 18(1) 270–280. DOI:10.1208/s12248-015-9846-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26597291
Minaei, AA, & Kowdley, KV (2015). ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert opinion on pharmacotherapy 16(6) 929–937. DOI:10.1517/14656566.2015.1024653 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25800085
Brayer, SW, & Reddy, KR (2015). Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. Expert review of gastroenterology & hepatology 9(5) 547–558. DOI:10.1586/17474124.2015.1032938 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25846301
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
| Pharmacolibrary.Types.TransferRate | ka (from PK_2C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_2C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)